
Avak Kahvejian. Flagship
Flagship bankrolls quest to create gene therapy 2.0, with new viral delivery tech in hand
Count Flagship Pioneering in for the long and convoluted chase of new delivery vehicles that promise to expand the booming gene therapy field.
Ring Therapeutics, its latest biotech creation, has a $50 million commitment to explore anellovectors — a whole new class of viral shells that it claims offers the first “real alternative” to adenovirus-associated viruses, or AAV, approaches. If proved viable, that could open up a whole new frontier into diseases that are currently off limits to gene therapy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters